Protection level of anti-hepatitis B vaccine in a pediatric Cameroonian population


  • Celine Nguefeu Nkenfou “Chantal Biya” International Reference Centre, Yaounde; Department of Biological Sciences, Yaounde, Cameroon
  • Merveille Kemenang School of Health Sciences, Catholic University of central Africa, Yaounde, Cameroon
  • Réné Essomba School of Health Sciences, Catholic University of central Africa, Yaounde; National Laboratory of Public Health, medical immunology and infectious diseases, Yaounde, Cameroon
  • Aubin Nanfack “Chantal Biya” International Reference Centre, Laboratory of immunology and microbiology, Yaounde, Cameroon
  • Paul-Fernand Endja Dominican Hospital Saint Martin de Porres, Yaounde, Cameroon



Hepatitis B; Mother to child transmission; HBV vaccine; protection level.


Background: Despite the availability for nearly twenty years of an effective vaccine, hepatitis B remains one of the most frequent viral diseases throughout the world. Mother-to-child transmission is one of the primary routes of transmission in children.

Objective: To assess the vaccine response in children born to HBV-infected mothers.

Methods: HBsAg-positive consenting mothers registered in the antenatal care (ANC) service database of Centre Hospitalier Dominicain St-Martin de Porres, Yaounde were enrolled with their children. Socio-demographic characteristics were collected using a tested questionnaire. The 5 markers of hepatitis B were tested and the quantification of anti-HBsAg antibodies was done by indirect ELISA method. The data collected was analyzed using Microsoft excel and Epi-info software.

Results: Out of 5,996 women registered, 143 were identified as HBsAg positive (2.38% prevalence), of which 50 were enrolled in the study. Of the 50 positive mothers, 78 children were included with a mean age ± standard deviation of 2.33 ± 2.86 years. No child was infected with HBV, but all have been exposed to the virus (HBeAb-positive). Overall 64 (82.05%) received at birth both anti-HBs immunoglobulin (HBIG) and a dose of vaccine, while 14 (17.95%) received only the birth dose of vaccine. 72 (92.31%) children received all three recommended doses of the vaccine. Vaccine responders were 62.82% (above 10 IU/mL), while 37.18% of children were non-responders; representing a higher risk group if not boosted.

Conclusion: The coverage of anti-HBV vaccine in children in this study was 92.31%. The protection level of 62.82% is below the 95% recommended rate by WHO. The factors sustaining this suboptimal protection should be investigated.

Download data is not yet available.




How to Cite

Nkenfou, C. N., Kemenang, M., Essomba, R., Nanfack, A., & Endja, P.-F. (2023). Protection level of anti-hepatitis B vaccine in a pediatric Cameroonian population. Journal of Public Health in Africa, 14(12).



Original Articles